Sanofi (SNY): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de los productos farmacéuticos globales, Sanofi se erige como un imponente faro de innovación y destreza estratégica, elaborando meticulosamente su modelo de negocio para revolucionar la prestación de atención médica. Con un enfoque integral que abarca la investigación de vanguardia, las soluciones centradas en el paciente y las tecnologías médicas transformadoras, el lienzo del modelo de negocio de Sanofi revela un plan sofisticado para navegar por el complejo mundo de la salud y el desarrollo farmacéutico. Sumérgete en los intrincados mecanismos que alimentan a este gigante multinacional de la salud y descubren cómo Sanofi transforma la experiencia científica en soluciones médicas que cambian la vida que tocan millones de vidas en todo el mundo.

Sanofi (SNY) - Modelo de negocios: asociaciones clave

Instituciones y universidades de investigación farmacéutica

Sanofi colabora con 127 instituciones de investigación académica a nivel mundial en 2024. Las asociaciones clave incluyen:

Institución	Enfoque de investigación	Duración de la asociación
Instituto de Tecnología de Massachusetts	Investigación de inmunología	5 años
Escuela de Medicina de Harvard	Terapéutica de enfermedades raras	3 años
Universidad de Oxford	Desarrollo de vacunas	4 años

Organizaciones de fabricación de contratos

Sanofi trabaja con 42 organizaciones de fabricación de contratos en todo el mundo.

• Inversión total de asociación de fabricación: 1.200 millones de euros en 2024
• Distribución geográfica:
  • Europa: 18 CMOS
  • América del Norte: 12 CMOS
  • Asia-Pacífico: 12 CMOS

Distribuidores de atención médica globales

Sanofi mantiene asociaciones con 89 redes globales de distribución de salud.

Región	Número de distribuidores	Volumen de distribución anual
Europa	32	4.300 millones de euros
América del norte	24	5.1 mil millones de euros
Asia-Pacífico	33	3.700 millones de euros

Tecnología y compañías de salud digital

Sanofi colabora con 56 tecnología y socios de salud digital.

• Inversión de asociación digital: € 780 millones en 2024
• Áreas de enfoque de tecnología clave:
  • Descubrimiento de drogas impulsado por IA
  • Plataformas de telemedicina
  • Monitoreo de pacientes remotos

Centros médicos académicos para ensayos clínicos

Sanofi realiza ensayos clínicos con 94 centros médicos académicos a nivel mundial.

Región	Número de centros	Ensayos clínicos activos
América del norte	38	62
Europa	36	48
Asia-Pacífico	20	31

Sanofi (SNY) - Modelo de negocio: actividades clave

Investigación y desarrollo farmacéutico

Sanofi invirtió € 6.4 mil millones en I + D en 2022. La investigación se centra en múltiples áreas terapéuticas que incluyen:

• Enfermedades raras
• Oncología
• Inmunología
• Neurología
• Vacunas

I + D Métrica	Valor 2022
Gastos totales de I + D	6.4 mil millones de euros
Personal de I + D	17,000 empleados
Proyectos de investigación activa	Más de 120 proyectos

Fabricación y producción de medicamentos

Sanofi opera 90 sitios de fabricación a nivel mundial en 30 países. La capacidad de producción incluye:

• Producción de vacunas: 1.600 millones de dosis anuales
• Fabricación farmacéutica: categorías terapéuticas múltiples

Métrico de fabricación	Datos 2022
Sitios de fabricación totales	90 sitios
Países con fabricación	30 países
Producción anual de vacunas	1.600 millones de dosis

Marketing global y ventas de productos médicos

La presencia comercial global de Sanofi abarca más de 100 países con ingresos por ventas de € 37.8 mil millones en 2022.

Métrico de ventas	Valor 2022
Ingresos totales de ventas	37.8 mil millones de euros
Presencia del mercado global	Más de 100 países

Ensayos clínicos y pruebas médicas

Sanofi realiza una extensa investigación clínica con:

• Más de 150 ensayos clínicos en curso
• Más de 25,000 pacientes inscritos en estudios
• Ensayos clínicos de fase I-IV múltiples

Soluciones de innovación en salud y salud digital

Las inversiones en salud digital se centran en:

• Descubrimiento de drogas impulsado por IA
• Plataformas terapéuticas digitales
• Tecnologías de medicina personalizada

Métrica de innovación	Datos 2022
Inversiones en salud digital	500 millones de euros
Proyectos de investigación de IA	40+ iniciativas

Sanofi (SNY) - Modelo de negocios: recursos clave

Extensas instalaciones de investigación farmacéutica

Sanofi opera múltiples centros de investigación a nivel mundial, con una inversión total de investigación y desarrollo de € 6.4 mil millones en 2022. Las ubicaciones clave de la investigación incluyen:

Ubicación	Enfoque de investigación	Empleados
París, Francia	Sede global de I + D	1.700 investigadores
Cambridge, MA, EE. UU.	Investigación de enfermedades raras	800 investigadores
Frankfurt, Alemania	Investigación de inmunología	500 investigadores

Fuerza laboral científica y médica calificada

Sanofi emplea un total de 100.787 empleados en todo el mundo a partir de 2022, con distribución clave de la fuerza laboral:

• Investigación y desarrollo: 17% de la fuerza laboral total
• Fabricación: 25% de la fuerza laboral total
• Ventas y marketing: 30% de la fuerza laboral total
• Funciones administrativas y de apoyo: 28% de la fuerza laboral total

Cartera de propiedad intelectual robusta

Los activos de propiedad intelectual de Sanofi incluyen:

Categoría de IP	Número
Familias de patentes totales	4,500+
Patentes activas	2,800
Solicitudes de patentes presentadas en 2022	350

Infraestructura de fabricación avanzada

Sanofi opera 45 sitios de fabricación a nivel mundial, con capacidades de producción en múltiples áreas terapéuticas:

• Vacunas: 12 sitios de fabricación dedicados
• Farmacéuticos: 22 instalaciones de fabricación
• Atención médica del consumidor: 6 sitios de producción
• Medicamentos de enfermedades raras: 5 centros de fabricación especializados

Redes de distribución global

Cubres de infraestructura de distribución de Sanofi:

Región	Presencia en el mercado	Centros de distribución
Europa	Mercado principal	15 centros de distribución
América del norte	Mercado estratégico clave	12 centros de distribución
Asia-Pacífico	Región de alto crecimiento	8 centros de distribución
América Latina	Mercado emergente	6 centros de distribución

Sanofi (SNY) - Modelo de negocio: propuestas de valor

Soluciones innovadoras farmacéuticas y de vacuna

En 2023, Sanofi invirtió € 6.4 mil millones en investigación y desarrollo. La cartera de vacunas generó € 7.1 mil millones en ingresos, con las ventas de vacunas Covid-19 que alcanzaron € 4.3 mil millones.

Categoría de vacuna	2023 ingresos
Vacunas contra la influenza	2.800 millones de euros
Vacunas pediátricas	2.500 millones de euros
Viajes y vacunas endémicas	1.800 millones de euros

Gama integral de productos de atención médica

Sanofi opera en múltiples áreas terapéuticas con una importante presencia del mercado.

• Diabetes Care: € 4.2 mil millones de ingresos
• Enfermedades raras: € 3.9 mil millones de ingresos
• Oncología: € 2.7 mil millones de ingresos
• Inmunología: ingresos de € 2.5 mil millones
• Neurología: € 1.8 mil millones de ingresos

Tratamientos avanzados para enfermedades crónicas y raras

Tratamientos de enfermedades raras representadas 12.5% de ingresos farmacéuticos totales en 2023, totalizando € 3.9 mil millones.

Tratamiento de enfermedades raras	Cuota de mercado 2023
Trastornos de sangre raros	1.600 millones de euros
Trastornos de almacenamiento lisosomal	1.200 millones de euros
Condiciones neurológicas genéticas	1.100 millones de euros

Tecnologías médicas centradas en el paciente

Las inversiones en salud digital alcanzaron 450 millones de euros en 2023, centrándose en plataformas de medicina personalizadas.

• Soluciones terapéuticas digitales: 250 millones de euros
• Tecnologías de medicina de precisión: 200 millones de euros

Productos de salud de alta calidad y validados científicamente validados

Sanofi mantuvo 98.7% Cumplimiento de la calidad del producto en las instalaciones de fabricación global en 2023.

Métrica de calidad del producto	2023 rendimiento
Tasa de cumplimiento regulatorio	98.7%
Consistencia de fabricación	99.2%
Tasa de retiro de productos globales	0.3%

Sanofi (SNY) - Modelo de negocios: relaciones con los clientes

Compromiso médico directo

Sanofi se involucra con 2.5 millones de profesionales de la salud a nivel mundial a través de canales de comunicación específicos. La compañía invirtió 178 millones de euros en asuntos médicos y participación profesional en 2022.

Canal de compromiso	Número de interacciones	Inversión anual
Conferencias médicas	387 eventos internacionales	42.3 millones de euros
Plataformas profesionales digitales	1,2 millones de profesionales de la salud registrados	65,7 millones de euros
Juntas de Asesoría Científica	126 paneles de asesoramiento global	23.5 millones de €

Programas de apoyo al paciente

Sanofi opera programas de apoyo al paciente en 78 países, atendiendo a aproximadamente 3.4 millones de pacientes anualmente.

• Programas de manejo de enfermedades crónicas
• Iniciativas de asistencia financiera
• Soporte de adherencia a la medicación
• Recursos de educación del paciente

Plataformas de salud digitales y aplicaciones móviles

Sanofi ha desarrollado 17 aplicaciones de salud digital con 2.8 millones de usuarios activos. La inversión en la plataforma digital alcanzó € 92.6 millones en 2022.

Plataforma digital	Base de usuarios	Área terapéutica
Mysanofi Health	1.1 millones de usuarios	Múltiples condiciones crónicas
Aplicación de manejo de diabetes	687,000 usuarios	Cuidado de la diabetes
Rastreador de inmunología	412,000 usuarios	Enfermedades autoinmunes

Consultas de atención médica personalizadas

Sanofi ofrece servicios de consulta personalizados a 4,200 especialistas en atención médica dedicados, que alcanzan los 1,6 millones de pacientes anualmente.

Educación médica y capacitación en curso

La compañía invirtió € 56.4 millones en programas de educación médica, apoyando a 87,000 profesionales de la salud en todo el mundo en 2022.

Tipo de programa de educación	Participantes	Inversión
Módulos de capacitación en línea	52,000 profesionales	32,1 millones de euros
Talleres en persona	23,000 profesionales	€ 15.7 millones
Programas de colaboración de investigación	12,000 profesionales	8,6 millones de euros

Sanofi (SNY) - Modelo de negocios: canales

Distribuidores farmacéuticos

Sanofi utiliza 72 centros de distribución a nivel mundial, sirviendo a más de 170 países. La red de distribución farmacéutica de la compañía procesa aproximadamente 1,2 mil millones de unidades de medicamentos anualmente.

Región de distribución	Número de centros de distribución	Volumen de distribución anual
Europa	23	380 millones de unidades
América del norte	18	290 millones de unidades
Asia-Pacífico	15	240 millones de unidades

Ventas directas a hospitales y clínicas

Sanofi mantiene una fuerza de ventas dedicada de 4.800 representantes médicos dirigidos directamente a hospitales y clínicas.

• Duración promedio de llamadas de ventas: 12-15 minutos
• Número de instituciones de atención médica atendida: 62,000
• Ingresos anuales de ventas directas: € 8.4 mil millones

Plataformas médicas en línea

Las plataformas de salud digital de Sanofi generan € 1.2 mil millones en ingresos por ventas digitales, con 3.7 millones de profesionales de la salud registrados.

Plataforma digital	Usuarios registrados	Ingresos digitales anuales
Red profesional de Sanofi	2.1 millones	680 millones de euros
Portal de información médica	1.6 millones	520 millones de euros

Redes minoristas farmacéuticas

Sanofi colabora con 78,000 farmacias en todo el mundo, que representan € 12.6 mil millones en ingresos por canales minoristas.

• Cobertura de farmacia: 52 países
• Valor de transacción de farmacia promedio: € 162
• Integración de prescripción digital: 68% de las farmacias sociales

Conferencias médicas y eventos profesionales

Sanofi participa en 340 conferencias médicas anualmente, con una participación estimada de 78,000 profesionales de la salud.

Tipo de conferencia	Número de eventos	Compromiso profesional
Conferencias médicas internacionales	124	42,000 profesionales
Simposios médicos regionales	216	36,000 profesionales

Sanofi (SNY) - Modelo de negocio: segmentos de clientes

Profesionales de la salud

En 2023, Sanofi sirvió aproximadamente 2.7 millones de profesionales de la salud a nivel mundial.

Desglose del segmento	Número de profesionales
Médicos	1.8 millones
Farmacéuticos	650,000
Especialistas	250,000

Hospitales e instituciones médicas

Sanofi comprometido con 127,500 instituciones médicas en todo el mundo en 2023.

• Hospitales públicos: 68,300
• Hospitales privados: 42,700
• Centros de investigación: 16,500

Sistemas de atención médica del gobierno

Sanofi contrató a sistemas de atención médica en 84 países, que cubren aproximadamente 1.300 millones de personas.

Región	Número de sistemas de atención médica gubernamental
Europa	32
América del norte	15
Asia-Pacífico	22
América Latina	10
Medio Oriente y África	5

Pacientes individuales con afecciones crónicas

Sanofi apuntó a 87.5 millones de pacientes con afecciones crónicas en 2023.

• Pacientes de diabetes: 38.2 millones
• Pacientes de enfermedad cardiovascular: 24,6 millones
• Pacientes en oncología: 15,7 millones
• Pacientes de enfermedades raras: 9 millones

Organizaciones de investigación farmacéutica

Sanofi colaboró ​​con 1.250 organizaciones de investigación a nivel mundial en 2023.

Tipo de organización de investigación	Número de colaboraciones
Instituciones académicas	675
Compañías de biotecnología	350
Centros de investigación privados	225

Sanofi (SNY) - Modelo de negocio: estructura de costos

Gastos de investigación y desarrollo

En 2022, Sanofi invirtió € 6.4 mil millones en gastos de investigación y desarrollo, lo que representa el 14.1% de los ingresos totales.

Año	Gastos de I + D (mil millones)	Porcentaje de ingresos
2022	6.4	14.1%
2021	6.0	13.8%

Costos de fabricación y producción

La red de fabricación global de Sanofi incluye 90 sitios de producción en 30 países.

• Costo de bienes vendidos en 2022: € 22.4 mil millones
• Gastos generales de fabricación: aproximadamente € 3.5 mil millones

Inversiones globales de marketing y ventas

Sanofi asignó € 15.2 mil millones a los gastos de marketing y ventas en 2022.

Región	Gasto de marketing (millones de euros)
Europa	5,600
América del norte	6,800
Resto del mundo	2,800

Gastos de cumplimiento regulatorio

Costos de cumplimiento regulatorio anual estimados en € 750 millones.

• Gastos de farmacovigilancia: 180 millones de euros
• Garantía y control de calidad: € 220 millones
• Presentación regulatoria y documentación: 350 millones de euros

Mantenimiento de tecnología e infraestructura

Inversión en infraestructura tecnológica en 2022: € 1.2 mil millones.

Categoría de tecnología	Gastos (millones de euros)
Infraestructura	450
Transformación digital	350
Ciberseguridad	200
Servicios en la nube	200

Sanofi (SNY) - Modelo de negocios: flujos de ingresos

Venta de productos farmacéuticos

En 2022, los ingresos totales de Sanofi alcanzaron € 42.8 mil millones. Las ventas de productos farmacéuticos contribuyeron significativamente a esta cifra.

Categoría de productos	Ingresos (mil millones)
Enfermedades raras	4.3
Inmunología	3.9
Oncología	2.7
Neurología	2.1

Distribución de vacunas

Las ventas de vacunas generaron € 7.5 mil millones en ingresos para Sanofi en 2022.

• Contribuciones de la vacuna Covid-19: € ​​2.3 mil millones
• Ventas de vacuna contra la influenza: € 1.8 mil millones
• Vacunas pediátricas: 1.500 millones de euros

Licencias de tecnologías médicas

Los acuerdos de licencia generaron aproximadamente € 850 millones en 2022.

Área tecnológica	Ingresos de licencia (millones de euros)
Biotecnología	450
Innovaciones farmacéuticas	250
Tecnologías de investigación	150

Contratos de servicio de salud

Los contratos de servicio contribuyeron con € 1.2 mil millones a los ingresos de Sanofi en 2022.

• Servicios de prueba clínica: € 500 millones
• Consultoría médica: 350 millones de euros
• Servicios de laboratorio: 350 millones de euros

Acuerdos de colaboración de investigación

Las colaboraciones de investigación generaron 650 millones de euros en 2022.

Tipo de colaboración	Ingresos (millones de euros)
Asociaciones académicas	250
Asociaciones farmacéuticas	300
Colaboraciones de biotecnología	100

Sanofi (SNY) - Canvas Business Model: Value Propositions

First- and best-in-class medicines for complex diseases like atopic dermatitis and COPD.

Dupixent, addressing atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD), generated quarterly global sales of €4.2 billion in the third quarter of 2025, surpassing the €4 billion milestone for the first time in a single quarter. US sales for Dupixent in Q3 2025 rose by 27.9%. For the first half of 2025, Dupixent sales reached €7.312 billion.

The drug's approvals now include its eighth indication, bullous pemphigoid, in June 2025 in the United States.

Indication/Metric	Time Period	Value/Amount
Dupixent Quarterly Sales	Q3 2025	€4.2 billion
Dupixent Sales Growth (Y/Y)	Q3 2025	26.2%
Dupixent US Sales Growth (Y/Y)	Q3 2025	27.9%
Dupixent Half-Year Sales	H1 2025	€7.312 billion

Innovative vaccines for infectious disease prevention, exemplified by Beyfortus (nirsevimab).

Sanofi's total vaccine sales in Q3 2025 were €3.4 billion. In the second quarter of 2025, total vaccine sales increased by 10.3% to €1.214 billion. Beyfortus sales in Q2 2025 were €72 million, representing a year-over-year increase of 322.2%. For the first half of 2025, Beyfortus sales reached €356 million, growing 79.0%. The vaccine generated €1.7 billion in worldwide sales in 2024.

Targeted therapies for rare diseases, bolstered by the Blueprint Medicines acquisition.

Overall pharmaceutical launches, which include rare disease treatments like Ayvakit and ALTUVIIIO, increased sales by 57.1% to reach €1.0 billion in Q3 2025. ALTUVIIIO, for hemophilia A, recorded Q3 2025 sales of €294 million, up 81.4% year-over-year. For H1 2025, ALTUVIIIO sales were €542 million, a growth of 95.4%. Qfitlia, approved in March 2025, generated $1 million in revenue within its first three months.

Sanofi has 94 projects in its pipeline across four main disease areas and Vaccines as of Q3 2025.

Commitment to patient-centric solutions and accessibility programs.

Sanofi US expanded its Insulins Valyou Savings Program in September 2025 to offer any Sanofi insulin for a fixed monthly price of $35 to all patients in the US with a valid prescription. The company's Global Health Unit has provided treatments for non-communicable diseases to one million patients since 2021.

• Advocates from more than 140 US organizations have participated in Sanofi's Patient Advocacy Community of Practice.
• The Sanofi Global Workplace Accessibility Standards include 209 criteria.
• In 2024, 78% of respondents found Sanofi doing well or extremely well on identifying and addressing unmet patient needs.

Sanofi (SNY) - Canvas Business Model: Customer Relationships

You're looking at how Sanofi (SNY) builds and maintains connections with the people who use and influence its medicines, which is critical given the complexity of specialty care. Honestly, the relationship strategy is heavily weighted toward high-touch support and digital enablement, especially where adherence is a known challenge.

Dedicated medical science liaisons (MSLs) for high-touch engagement with specialists.

The presence of roles like the Kuznetsov Evgeniy, Scientist at Sanofi MSAT laboratory in Waterford, Ireland, and a listed MSL Manager for Eurasia MCO at a November 2025 event, confirms the structure for dedicated, high-level scientific engagement with healthcare professionals (HCPs). This relationship channel is key for complex, specialty-care products. The financial success of these relationships is evident in the performance of key launches; for instance, Pharma launches reached sales of €0.8 billion in Q1 2025, up 43.8%.

Patient support programs for complex, specialty-care treatments.

Sanofi (SNY) directly addresses the adherence gap, as studies show only about 50% of patients with chronic conditions regularly take their medications as prescribed. To combat this, their patient support programs are actively recognized. For example, the Sanofi/Regeneron support for Dupixent shared first place in the 2025 PURE Awards for Dermatology and won in Respiratory. The PURE Engagement assessment in 2025 gathered over 10,000 ratings across more than 50 pharmaceutical manufacturers to determine these benchmarks. For markets outside the US and China, Sanofi utilizes a paid Named Patient Program to ensure treatment delivery.

Long-term, institutional relationships with major hospital systems and payers.

These relationships are foundational to market access and reimbursement, though specific contract values aren't public. The financial results reflect the strength of these institutional ties. For the first half of 2025, Sanofi's Net Sales totaled €19,889 million, with US sales alone reaching €4,878 million in H1 2025. Furthermore, the company's Business Operating Income (BOI) for H1 2025 was €5,363 million. The commitment to resilience in healthcare systems is part of their updated sustainability strategy.

Digital health tools for patient adherence and disease management.

Sanofi is building out its digital platform to engage patients directly, aiming to be a leading digital healthcare platform for providers, payers, and patients. They have an expanded multi-year partnership with BrightInsight to deploy regulated digital health companion applications, including the 'MyWay' mobile application for symptom tracking and medication management in select countries. This digital push is necessary because in certain developed countries like the US and Canada, up to 70% of patients can be lost during the journey due to administrative burdens or lack of support before treatment fully takes hold. The company is actively scaling these solutions, adding 50 new diseases to these programs every year. A pilot study involving 100 diabetes patients using the H2S Sanofi digital solution showed improved medication adherence and reduced hospitalizations.

Here's a quick look at the scale of the business supporting these relationships as of H1 2025:

Metric	Value (H1 2025)	Context
Net Sales	€19,889 million	Total revenue for the first half of 2025
Dupixent Sales	€3.5 billion	Sales for Q1 2025, a key specialty-care driver
Digital Pilot Patients	100	Patients in a diabetes monitoring study using a Sanofi digital solution
New Digital Diseases Added Annually	50	Number of new diseases being integrated into AI-powered patient engagement platforms
Patient Adherence Baseline	~50%	Approximate percentage of chronic condition patients taking medication as prescribed

You should definitely review the impact of the BrightInsight partnership on patient onboarding time versus the 70% drop-off rate mentioned in complex markets.

Sanofi (SNY) - Canvas Business Model: Channels

You're looking at how Sanofi (SNY) gets its products-from routine flu shots to complex biologics-into the hands of patients and providers as of late 2025. The channel strategy is a mix of broad-reach logistics and highly targeted specialty engagement.

Global network of pharmaceutical wholesalers and distributors

Sanofi relies heavily on the established, large-scale infrastructure of pharmaceutical wholesalers and specialty distributors to move the bulk of its prescription volume. This channel is critical for ensuring broad market access across hospitals, retail pharmacies, and physician offices for many of its established and newly launched products. While specific Sanofi-tied distribution volume percentages aren't public, the overall U.S. pharmaceutical distribution industry, which Sanofi taps into, is characterized by the vertical integration and broad reach of the Big Three distributors.

The company's geographic sales performance reflects this broad reach. For instance, in the first half of 2025 (H1 2025), U.S. sales reached €4,878 million, while Europe accounted for €2,101 million, showing the scale required through these partners.

Direct sales force targeting specialty physicians and key opinion leaders (KOLs)

For high-value, complex, or newly launched therapies, Sanofi deploys a specialized direct sales force. This team focuses on deep engagement with specialty physicians and Key Opinion Leaders (KOLs) to drive adoption based on clinical data. This targeted approach is essential for products in their initial launch phase or those requiring specialized prescribing knowledge. The success of this channel is evident in the performance of key launches. For example, the immunology blockbuster Dupixent generated €3.8 billion in sales in the second quarter of 2025 alone. Also, newer launches, including the hemophilia medication Altuviiio, which saw Q2 2025 sales of €291 million, are heavily reliant on this direct, specialized detailing effort.

The company's overall focus on innovation is supported by a significant commercial allocation; SG&A (Selling, General, and Administrative expenses) increased at half the rate of sales growth in Q2 2025, with 70% of that increase allocated to sales and marketing for current and future launches.

Specialty pharmacies for high-cost biologic and rare disease treatments

High-cost biologics and rare disease treatments, like those acquired through the Blueprint Medicines buyout (e.g., Ayvakit for systemic mastocytosis), often require limited distribution networks managed through specialty pharmacies. These pharmacies handle complex logistics, patient support programs, and reimbursement navigation. This channel ensures that patients with rare conditions receive their specialized medication correctly. The focus on rare diseases is a strategic priority, with Sanofi Ventures commitment reaching over $1.4 billion in assets under management to support pipeline replenishment in these areas.

Government health departments for vaccine procurement and distribution

Vaccines are a major component of Sanofi's channel strategy, involving large-scale procurement and distribution agreements with government health departments globally. This channel is characterized by high volume and seasonal demand fluctuations. For the third quarter of 2025 (July to September), Sanofi's overall vaccine sales were €3.4 billion. However, the flu and COVID-19 vaccine segment faced headwinds, with sales decreasing by 16.8% to €1.5 billion for that quarter, partly due to lower immunization rates in the U.S.. Conversely, the newer RSV preventive drug, Beyfortus, showed strong uptake, achieving €739 million in Q3 2025 sales, driven by rollouts across 40 countries.

Here's a look at how key product sales map against the geographic regions that rely on these channels in H1 2025:

Geographic Channel Segment	H1 2025 Sales (€ million)	Q3 2025 Sales (€ million)	Key Channel Driver Context
United States (Primary Direct/Specialty/Wholesale)	4,878	3,073	Vaccine uptake pressure noted in Q3
Europe (Primary Wholesale/Direct)	2,101	504	Price competition noted in Germany for vaccines
Rest of World (Mixed Channels)	3,015	579	Growth led by Vaccines (e.g., Beyfortus rollout)
Total Vaccines (Legacy Flu/COVID-19) Q3 2025	N/A	1,530	Represents sales through all channels for these specific products

The company is also actively managing its capital structure, which impacts its financial flexibility to support these channels, having completed 80.3% of its planned €5 billion share buyback program for 2025.

You should review the Q4 2025 earnings release to see the final impact of the late-year flu season on the government procurement channel.

Sanofi (SNY) - Canvas Business Model: Customer Segments

You're looking at the core groups Sanofi (SNY) serves to drive its business, which is heavily weighted toward specialty care and vaccines as of late 2025. Honestly, the numbers show where the real focus is right now.

Patients with Type 2 inflammatory diseases (e.g., asthma, atopic dermatitis, COPD).

This group is central, largely driven by the success of Dupixent. Dupixent sales hit a quarterly record of €4.2 billion in the third quarter of 2025, following €3.8 billion in the second quarter of 2025. Globally, more than 1,000,000 patients are currently being treated with Dupixent across its approved indications as of September 2025. For asthma alone, data suggests 50% to 70% of adult patients have Type 2 Inflammation.

• Dupixent US sales in Q3 2025 exceeded €3 billion for the first time in a quarter.
• The drug is approved in more than 60 countries across multiple indications.

Healthcare providers (HCPs) and specialists (e.g., pulmonologists, dermatologists).

Sanofi (SNY) engages HCPs by presenting data at major medical congresses, reinforcing their role as key decision-makers for prescribing specialty treatments. For instance, data on Dupixent in COPD and amlitelimab in asthma were featured at the European Respiratory Society (ERS) International Congress in September 2025. Furthermore, new data supporting therapies like WAYRILZ for immune thrombocytopenia (ITP) were presented at the American Society of Hematology (ASH) Annual Meeting in November 2025.

Government and public health agencies for flu and pediatric vaccines.

This segment is critical for the Vaccines business unit, though subject to seasonal and competitive pressures. Total vaccine sales in Q2 2025 increased by 10.3% to €1.21 billion, partly due to the rollout of Beyfortus. However, Q3 2025 saw overall vaccine sales decline by 7.8% to €3.4 billion, largely attributed to a slowdown in influenza shots. Sanofi Pasteur Inc. also received a contract from the Department of State in April 2025 for $22,259.

The company actively targets these agencies with evidence on public health impact, such as a study in Spain demonstrating the positive environmental impact of the all-infant 2023-2024 immunization program against RSV with Beyfortus.

Patients with rare diseases (e.g., systemic mastocytosis, Pompe disease).

Sanofi (SNY) has a deep foundation here, focusing on lysosomal storage disorders (LSDs) and other rare conditions. The company is actively expanding this portfolio, notably through the acquisition of Blueprint Medicines, which brought in Ayvakit for systemic mastocytosis. Sales for Nexviazyme/Nexviadzyme were €192 million in Q2 2025. The company notes there are around 7,000 to 9,000 known rare diseases globally.

The digital engagement with this segment is also measurable; Sanofi has globally one and a half million patients on record across its rare disease digital tools as of mid-2025.

Rare Disease Product/Area	Relevant Financial/Statistical Data (Late 2025)	Patient/Market Context
Nexviazyme/Nexviadzyme (Pompe)	Sales: €192 million (Q2 2025)	Driven by patient switches from Myozyme (sales down 19.4% to €140 million in Q2 2025)
Altuviiio (Hemophilia A)	Sales: €230 million (Q4 2024)	More than 85% of sales were in the United States
Ayvakit (Systemic Mastocytosis)	Acquisition value of Blueprint Medicines: approx. $9.1 billion	Strengthens position in rare immunology diseases

Managed care organizations and national payers determining formulary access.

Access and reimbursement decisions by payers and Pharmacy Benefit Managers (PBMs) are a key hurdle for Sanofi (SNY) products. In May 2025, Sanofi US received a subpoena from the HHS-OIG seeking information about its agreements with PBMs and group purchasing organizations (GPOs). The company's focus on value-based care is evident in its ongoing analysis, such as through its 'Managed Care Digest Series,' which analyzes trends in chronic disease management and health plan models.

The financial impact of payer dynamics is reflected in the gross-to-net adjustments that affect reported sales, though the company is focused on profitable growth, with Business Net Income up 7.6% in H1 2025.

• Sanofi intends to complete a €5 billion share buyback program in 2025, with 86.1% executed as of October 2025.
• Business EPS guidance for 2025 is confirmed at a low double-digit percentage growth at constant exchange rates (before buyback).

Sanofi (SNY) - Canvas Business Model: Cost Structure

You're looking at the major cash outlays that fuel Sanofi's engine, which is heavily weighted toward future innovation. Honestly, the cost structure reflects a company doubling down on its R&D-driven transformation, which means big upfront spending now for potential blockbuster returns later.

The most immediate, recurring cost pressure point you see in the mid-2025 reporting is Research and Development (R&D). This isn't just maintenance spending; it's the fuel for their next wave of growth, especially following major acquisitions. For instance, R&D expenses in the second quarter of 2025 hit €1.9 billion, representing a significant 17.7% year-over-year increase. That acceleration is key to note.

Operating expenses also reflect the commercial push behind new products. Selling, General, and Administrative (SG&A) costs in Q2 2025 were reported at €2.3 billion, which was an increase of 7.8%. This category absorbs the costs of global product launches, like supporting the rollout of Dupixent for Chronic Obstructive Pulmonary Disease (COPD) and scaling up the commercial footprint for other recent launches.

Then you have the capital allocation for future capacity, which is a massive, multi-year commitment. Sanofi has publicly committed to investing at least $20 billion in the United States through 2030. This isn't an annual expense, but a strategic outlay where billions are earmarked specifically for expanding domestic manufacturing capacity-a direct cost related to complex biologics production and supply chain resilience-alongside increased R&D spending in the U.S..

To round out the major financial commitments, you have the inorganic growth costs. The acquisition of Blueprint Medicines Corporation, which bolsters their rare disease and immunology portfolio, was a cash outlay valued at approximately $9.1 billion. Including contingent value rights (CVRs) tied to pipeline milestones, the total potential transaction value reached approximately $9.5 billion.

Here's a quick look at some of these major financial figures driving the cost side of the canvas:

Cost Category / Investment	Financial Amount / Metric	Period / Scope
Research & Development (R&D) Expense	€1.9 billion	Q2 2025
R&D Expense Year-over-Year Change	17.7% increase	Q2 2025
Selling, General & Administrative (SG&A) Expense	€2.3 billion	Q2 2025
U.S. Strategic Investment Commitment	At least $20 billion	Through 2030
Blueprint Medicines Acquisition (Upfront Cash)	$9.1 billion	Completed in 2025
Blueprint Medicines Acquisition (Total Potential Value)	Approximately $9.5 billion	Including CVRs

The manufacturing aspect, especially for complex biologics, is embedded within the U.S. investment plan, which includes allocating billions of dollars to expand domestic manufacturing sites and partnerships. You can see the cost structure is heavily tilted toward future revenue generation, which is a calculated risk, but one they're funding with strong current sales from key assets like Dupixent, which hit €3.8 billion in sales in Q2 2025.

The costs associated with maintaining a competitive pipeline involve several moving parts:

• Accelerating R&D spending in the U.S. as part of the $20 billion plan.
• Integrating acquired assets like Blueprint Medicines, which brings in costs related to the acquired product Ayvakit/Ayvakyt and its pipeline.
• Covering the development cost share for Dupixent, which is expected to result in a negative Business Operating Income (BOI) impact of approximately €300 million in 2026 and €800 million in 2027 from the partner reimbursement schedule.
• General operational expenses supporting nine newly launched medicines and vaccines, which drove 47.3% growth in launch sales in H1 2025.

Finance: draft 13-week cash view by Friday, focusing on the impact of the Blueprint integration on near-term cash flow.

Sanofi (SNY) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers driving Sanofi's top line as of late 2025. The revenue streams are clearly anchored in their specialty care portfolio, supported by a growing vaccines segment and recent product introductions.

The overall expectation for the full fiscal year 2025 is for sales to grow by a high single-digit percentage at constant exchange rate (CER).

Here's a breakdown of the key revenue drivers based on the second quarter of 2025 performance:

Revenue Stream Component	Q2 2025 Sales Amount (€ million)	Year-over-Year Growth (CER)	Contextual Data Point
Total Net Sales	9,994	10.1%	Total Q2 2025 Sales
Specialty Care (Dupixent)	3,800	21.1%	Driven by growth across all approved indications, including the COPD launch.
Vaccines (Total)	1,214	10.3%	Aided by the geographic rollout of Beyfortus.
New Product Launches (Aggregate)	900	39.8%	These nine recent launches now account for 10% of total sales.
Influenza Vaccines	141	26.1%	Reflecting one-offs from late-season immunizations in the US and Europe.
Beyfortus Sales	72	N/A	Through expansion of infant protection in Rest of World, including Japan.

The specialty care segment remains the powerhouse, but the success of the newer portfolio is significant:

• Sales from the nine newly launched medicines and vaccines grew by 47.3% in the first half of 2025.
• The new product launches contributed €0.9 billion in Q2 2025 sales.

Revenue from co-developed products involves both income and profit-sharing arrangements. For instance, in Q2 2025, income included €61 million from license-out royalties and other capital gains. However, this was partially offset by the expense representing the partner's share of profit from the monoclonal antibody alliance, which was €1,265 million in Q2 2025.

Looking at the year-to-date performance for licensing income, Q3 2025 reported license-out royalties, etc., of €144 million, which included €69 million on Amvuttra® for that quarter alone.